Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TNBC: Adding capecitabine boosts disease-free survival in prospective trial

Publish date:: December 13, 2019

Key clinical point: For patients with early triple-negative breast cancer, adding capecitabine to standard adjuvant chemotherapy may extend disease-free survival.

Major finding: The 5-year disease-free survival was 86.26% in the capecitabine group, compared with 80.23% in the control group (P = .038).

Study details: An open-label, phase 3 trial involving 585 patients with triple-negative breast cancer.

Disclosures: The investigators reported no disclosures.

Citation:

Li J et al. SABCS 2019, Abstract GS1-08.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,